articleThe LancetMar 9, 2016Closed access

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

LFLouis FehrenbacherAIAlexander I. SpiraMBMarcus BallingerMKMarcin KowanetzJVJohan Vansteenkiste

Kaiser Permanente Vallejo Medical Center · Virginia Cancer Specialists · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,798
total citations
FWCI
185.04
Percentile
100%
References
36
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Atezolizumab
  • Medicine
  • Docetaxel
  • Oncology
  • Internal medicine
  • Lung cancer
  • Population
  • Cancer
No related works found for this paper.

Funding